Title

Quantitative Evaluation of Biomarkers for TGF-β-Induced Epithelial-Mesenchymal Transition in Biochemical, Cellular, and 3D Spheroid Model Systems
Abstract Epithelial-mesenchymal transition (EMT) is a cellular differentiation process where epithelial cells lose many epithelial features, while acquiring mesenchymal cell-like properties, leading to reduced cell‒cell contacts and increased motility. While important for normal development, EMT can be co-opted by malignant epithelial tumors during metastasis. The TGF-β signaling pathway, comprising extracellular ligands, cell surface kinase receptors, and the SMAD family of signal transduction proteins is a potent inducer of EMT. Ligand binding to TGF-β-family receptors leads to receptor dimerization and kinase activation through autophosphorylation, which induces recruitment and phosphorylation of receptor-mediated SMAD proteins. Activated SMAD proteins form a protein complex that translocates to the nucleus, where it modulates the expression of numerous EMT- and metastasis-associated genes, including HMGA2, ZEB1, SNAI1, and Slug. In this webinar, we describe high-throughput methods to investigate TGF-β-induced EMT in biochemical, 2D cellular and 3D spheroid adenocarcinoma models, using rigorously validated immunoassay reagents from Cell Signaling Technology and the Agilent BioTek Cytation C10 confocal imaging reader.

Learning Objectives:
  • Immunoassay reagent selection
  • High-content experimental format and sample preparation
  • Imaging and analysis of 2D and 3D cellular models of EMT
 

DE48549188
Presenter
Scott Marshall Ernest Heimsath,
Ph.D.; Application Development Scientist,
Agilent Cell Analysis
Scott Marshall Antony W. Wood,
Ph.D.; Senior Director, Product Design & Strategy,
Cell Signaling Technology